DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Virtual Event

2021 年 10 月 13 日 9:50 上午 - 2021 年 10 月 14 日 5:15 下午

(US Eastern Standard Time)

Horsham, PA 19044

Special Topic: Risk Management in Combination Product Development

This event is now offered in a new entirely virtual format.

Session 6: Informational Session with EU

Session Chair(s)

Susan  Neadle, MS

Susan Neadle, MS

Principal Consultant and President

Combination Products Consulting Services LLC, United States

Regulatory frameworks are being introduced around the globe in efforts to ensure safe, efficacious and usable combination products for patients. Most recently, EMA has implemented updated combination products legislation under EU MDR (2017/745), and additional updates to pharmaceutical legislation are under consideration. This informational session will review Combination Products interpretation and expectations under EU MDR, and roles of EMA, National Competent Authorities and Notified bodies in the process.

Learning Objective :
  • Evaluate the interpretation and expectations of combination products under EU MDR
  • Distinguish roles and responsibilities of EMA, Competent Authorities and Notified Bodies as part of the process
  • Recognize evolving efforts under pharmaceutical legislation in EU

Speaker(s)

Christelle  Bouygues, PharmD

Speaker

Christelle Bouygues, PharmD

European Medicines Agency, Netherlands

Regulatory Affairs Senior Officer

Christiana  Hoffman, DrSc

Speaker

Christiana Hoffman, DrSc

TÜV SÜD bei TÜV SÜD, United States

Regional Manager Focus topics

Theresa  Jeary, MSc

Speaker

Theresa Jeary, MSc

BSI, United Kingdom

Technical Specialist & Scheme Manager

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。